Back to top
more

Corcept Therapeutics (CORT)

(Real Time Quote from BATS)

$70.54 USD

70.54
307,608

+0.09 (0.13%)

Updated Aug 6, 2025 02:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (83 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Oracle, American Healthcare, Palantir in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Zacks Equity Research

Corcept Shares Rise More Than 60% in Three Months: Here's Why

by Zacks Equity Research

CORT's Cushing's syndrome drug, Korlym, is driving revenues. The NDA for relacorilant in Cushing's syndrome will be filed shortly.

Zacks Equity Research

3 Reasons Growth Investors Will Love Corcept (CORT)

by Zacks Equity Research

Corcept (CORT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 37.9% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Corcept (CORT) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Corcept (CORT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

by Zacks Equity Research

Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.

Kinjel Shah headshot

5 Small Drug Stocks to Buy as Trump Gets Re-Elected

by Kinjel Shah

Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.

Nalak Das headshot

5 Stocks With Recent Price Strength to Tap Wall Street Rally

by Nalak Das

Investors target stocks that are witnessing a bull run. Some of the stocks seeing price strength are CDXC, SEZL, TILE, BGC, CORT.

Zacks Equity Research

Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Catalyst (CPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?

by Zacks Equity Research

Investors should invest in CORT right now as the stock is doing extremely well in 2024 and its prospects look even brighter.

Zacks Equity Research

Here is Why Growth Investors Should Buy Corcept (CORT) Now

by Zacks Equity Research

Corcept (CORT) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Corcept (CORT) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Best Momentum Stocks to Buy for November 5th

by Zacks Equity Research

CORT, ZBRA and QUAD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 5, 2024.

Zacks Equity Research

Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

New Strong Buy Stocks for November 5th

by Zacks Equity Research

AAT, QUAD, CORT, CMA and ADT have been added to the Zacks Rank #1 (Strong Buy) List on November 5, 2024.

Zacks Equity Research

Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 56.7% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Recent Price Trend in Corcept (CORT) is Your Friend, Here's Why

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy?

by Zacks Equity Research

Corcept (CORT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

by Zacks Equity Research

CORT beats on both earnings and sales in the third quarter of 2024. The company increases the revenue guidance for 2024. Stock falls in after-hours trading.

Zacks Equity Research

Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Corcept (CORT) delivered earnings and revenue surprises of 51.85% and 6.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Nilanjan Banerjee headshot

Buy Low-Beta Stocks JD, SKWD, CORT, PRA to Beat Election Uncertainty

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. JD, SKWD, CORT & PRA are well-poised to gain.

Zacks Equity Research

Zacks.com featured highlights Idaho Strategic, Qifu, Sezzle, Corcept and FinWise

by Zacks Equity Research

Idaho Strategic, Qifu, Sezzle, Corcept and FinWise have been highlighted in this Screen of The Week article.